Effective Use of Angiotensin II in Coronavirus Disease 19-Associated Mixed Shock State: A Case Report.
Identifieur interne : 000624 ( Main/Exploration ); précédent : 000623; suivant : 000625Effective Use of Angiotensin II in Coronavirus Disease 19-Associated Mixed Shock State: A Case Report.
Auteurs : Kevin A. Bobeck [États-Unis] ; Arthur W. Holtzclaw ; Tara E. Brown ; Paul A. ClarkSource :
- A&A practice [ 2575-3126 ] ; 2020.
Descripteurs français
- KwdFr :
- Angiotensine-II (usage thérapeutique), Betacoronavirus (MeSH), Choc (traitement médicamenteux), Choc (étiologie), Femelle (MeSH), Humains (MeSH), Infections à coronavirus (complications), Pandémies (MeSH), Pneumopathie virale (complications), Sujet âgé de 80 ans ou plus (MeSH), Vasoconstricteurs (usage thérapeutique).
- MESH :
- traitement médicamenteux : Choc.
- usage thérapeutique : Angiotensine-II, Infections à coronavirus, Pneumopathie virale, Vasoconstricteurs.
- étiologie : Choc.
- Betacoronavirus, Femelle, Humains, Pandémies, Sujet âgé de 80 ans ou plus.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Angiotensin II, Vasoconstrictor Agents.
- complications : Coronavirus Infections, Pneumonia, Viral.
- drug therapy : Shock.
- etiology : Shock.
- Aged, 80 and over, Betacoronavirus, Female, Humans, Pandemics.
Abstract
The rapid spread of Coronavirus Disease 2019 (COVID-19) has sparked a search for effective therapies. The discovery that the virus binds the angiotensin-converting enzyme 2 (ACE2) receptor has led to investigation of the renin-angiotensin system for possible therapeutic targets. We present a case of an elderly woman with multiple comorbidities who developed severe acute respiratory distress syndrome (ARDS), a cardiomyopathy, and vasodilatory shock secondary to COVID-19 and was treated with exogenous angiotensin II. She rapidly demonstrated significant hemodynamic improvement without noted adverse effects. Thus, we propose further investigation into possible benefits of angiotensin II in shock secondary to COVID-19.
DOI: 10.1213/XAA.0000000000001221
PubMed: 32784326
PubMed Central: PMC7172437
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effective Use of Angiotensin II in Coronavirus Disease 19-Associated Mixed Shock State: A Case Report.</title>
<author><name sortKey="Bobeck, Kevin A" sort="Bobeck, Kevin A" uniqKey="Bobeck K" first="Kevin A" last="Bobeck">Kevin A. Bobeck</name>
<affiliation wicri:level="2"><nlm:affiliation>From the Departments of *Internal Medicine †Pulmonary, Walter Reed National Military Medical Center, Bethesda, Maryland.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>From the Departments of *Internal Medicine †Pulmonary, Walter Reed National Military Medical Center, Bethesda</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Holtzclaw, Arthur W" sort="Holtzclaw, Arthur W" uniqKey="Holtzclaw A" first="Arthur W" last="Holtzclaw">Arthur W. Holtzclaw</name>
</author>
<author><name sortKey="Brown, Tara E" sort="Brown, Tara E" uniqKey="Brown T" first="Tara E" last="Brown">Tara E. Brown</name>
</author>
<author><name sortKey="Clark, Paul A" sort="Clark, Paul A" uniqKey="Clark P" first="Paul A" last="Clark">Paul A. Clark</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32784326</idno>
<idno type="pmid">32784326</idno>
<idno type="doi">10.1213/XAA.0000000000001221</idno>
<idno type="pmc">PMC7172437</idno>
<idno type="wicri:Area/Main/Corpus">000706</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000706</idno>
<idno type="wicri:Area/Main/Curation">000706</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000706</idno>
<idno type="wicri:Area/Main/Exploration">000706</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Effective Use of Angiotensin II in Coronavirus Disease 19-Associated Mixed Shock State: A Case Report.</title>
<author><name sortKey="Bobeck, Kevin A" sort="Bobeck, Kevin A" uniqKey="Bobeck K" first="Kevin A" last="Bobeck">Kevin A. Bobeck</name>
<affiliation wicri:level="2"><nlm:affiliation>From the Departments of *Internal Medicine †Pulmonary, Walter Reed National Military Medical Center, Bethesda, Maryland.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>From the Departments of *Internal Medicine †Pulmonary, Walter Reed National Military Medical Center, Bethesda</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Holtzclaw, Arthur W" sort="Holtzclaw, Arthur W" uniqKey="Holtzclaw A" first="Arthur W" last="Holtzclaw">Arthur W. Holtzclaw</name>
</author>
<author><name sortKey="Brown, Tara E" sort="Brown, Tara E" uniqKey="Brown T" first="Tara E" last="Brown">Tara E. Brown</name>
</author>
<author><name sortKey="Clark, Paul A" sort="Clark, Paul A" uniqKey="Clark P" first="Paul A" last="Clark">Paul A. Clark</name>
</author>
</analytic>
<series><title level="j">A&A practice</title>
<idno type="eISSN">2575-3126</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged, 80 and over (MeSH)</term>
<term>Angiotensin II (therapeutic use)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Coronavirus Infections (complications)</term>
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (complications)</term>
<term>Shock (drug therapy)</term>
<term>Shock (etiology)</term>
<term>Vasoconstrictor Agents (therapeutic use)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Angiotensine-II (usage thérapeutique)</term>
<term>Betacoronavirus (MeSH)</term>
<term>Choc (traitement médicamenteux)</term>
<term>Choc (étiologie)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Infections à coronavirus (complications)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (complications)</term>
<term>Sujet âgé de 80 ans ou plus (MeSH)</term>
<term>Vasoconstricteurs (usage thérapeutique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiotensin II</term>
<term>Vasoconstrictor Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Shock</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Shock</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Choc</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Angiotensine-II</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
<term>Vasoconstricteurs</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Choc</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged, 80 and over</term>
<term>Betacoronavirus</term>
<term>Female</term>
<term>Humans</term>
<term>Pandemics</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Betacoronavirus</term>
<term>Femelle</term>
<term>Humains</term>
<term>Pandémies</term>
<term>Sujet âgé de 80 ans ou plus</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The rapid spread of Coronavirus Disease 2019 (COVID-19) has sparked a search for effective therapies. The discovery that the virus binds the angiotensin-converting enzyme 2 (ACE2) receptor has led to investigation of the renin-angiotensin system for possible therapeutic targets. We present a case of an elderly woman with multiple comorbidities who developed severe acute respiratory distress syndrome (ARDS), a cardiomyopathy, and vasodilatory shock secondary to COVID-19 and was treated with exogenous angiotensin II. She rapidly demonstrated significant hemodynamic improvement without noted adverse effects. Thus, we propose further investigation into possible benefits of angiotensin II in shock secondary to COVID-19.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32784326</PMID>
<DateCompleted><Year>2020</Year>
<Month>08</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>08</Month>
<Day>24</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2575-3126</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>14</Volume>
<Issue>6</Issue>
<PubDate><Year>2020</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>A&A practice</Title>
<ISOAbbreviation>A A Pract</ISOAbbreviation>
</Journal>
<ArticleTitle>Effective Use of Angiotensin II in Coronavirus Disease 19-Associated Mixed Shock State: A Case Report.</ArticleTitle>
<Pagination><MedlinePgn>e01221</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1213/XAA.0000000000001221</ELocationID>
<Abstract><AbstractText>The rapid spread of Coronavirus Disease 2019 (COVID-19) has sparked a search for effective therapies. The discovery that the virus binds the angiotensin-converting enzyme 2 (ACE2) receptor has led to investigation of the renin-angiotensin system for possible therapeutic targets. We present a case of an elderly woman with multiple comorbidities who developed severe acute respiratory distress syndrome (ARDS), a cardiomyopathy, and vasodilatory shock secondary to COVID-19 and was treated with exogenous angiotensin II. She rapidly demonstrated significant hemodynamic improvement without noted adverse effects. Thus, we propose further investigation into possible benefits of angiotensin II in shock secondary to COVID-19.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bobeck</LastName>
<ForeName>Kevin A</ForeName>
<Initials>KA</Initials>
<AffiliationInfo><Affiliation>From the Departments of *Internal Medicine †Pulmonary, Walter Reed National Military Medical Center, Bethesda, Maryland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Holtzclaw</LastName>
<ForeName>Arthur W</ForeName>
<Initials>AW</Initials>
</Author>
<Author ValidYN="Y"><LastName>Brown</LastName>
<ForeName>Tara E</ForeName>
<Initials>TE</Initials>
</Author>
<Author ValidYN="Y"><LastName>Clark</LastName>
<ForeName>Paul A</ForeName>
<Initials>PA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>A A Pract</MedlineTA>
<NlmUniqueID>101714112</NlmUniqueID>
<ISSNLinking>2575-3126</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014662">Vasoconstrictor Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>11128-99-7</RegistryNumber>
<NameOfSubstance UI="D000804">Angiotensin II</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000804" MajorTopicYN="N">Angiotensin II</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012769" MajorTopicYN="N">Shock</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014662" MajorTopicYN="N">Vasoconstrictor Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>8</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>8</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>8</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32784326</ArticleId>
<ArticleId IdType="doi">10.1213/XAA.0000000000001221</ArticleId>
<ArticleId IdType="pii">02054229-202004000-00039</ArticleId>
<ArticleId IdType="pmc">PMC7172437</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Crit Care. 2017 Feb;37:206-210</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27969572</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Mar 23;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32203977</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care Med. 2018 Jun;46(6):949-957</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29509568</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Microbiol. 2020 Apr;5(4):562-569</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32094589</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Pept. 2012;2012:256294</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22536270</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care. 2018 Oct 28;22(1):274</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30368243</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci China Life Sci. 2020 Mar;63(3):364-374</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32048163</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Oral Sci. 2020 Feb 24;12(1):8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32094336</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1723-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21108554</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2017 Dec 28;377(26):2604</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29281568</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Heart Fail. 2016 Jan;18(1):8-27</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26548803</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anesth Analg. 2020 Jul;131(1):102-105</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32209811</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2012;7(4):e35797</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22563403</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
</region>
</list>
<tree><noCountry><name sortKey="Brown, Tara E" sort="Brown, Tara E" uniqKey="Brown T" first="Tara E" last="Brown">Tara E. Brown</name>
<name sortKey="Clark, Paul A" sort="Clark, Paul A" uniqKey="Clark P" first="Paul A" last="Clark">Paul A. Clark</name>
<name sortKey="Holtzclaw, Arthur W" sort="Holtzclaw, Arthur W" uniqKey="Holtzclaw A" first="Arthur W" last="Holtzclaw">Arthur W. Holtzclaw</name>
</noCountry>
<country name="États-Unis"><region name="Maryland"><name sortKey="Bobeck, Kevin A" sort="Bobeck, Kevin A" uniqKey="Bobeck K" first="Kevin A" last="Bobeck">Kevin A. Bobeck</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000624 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000624 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidSeniorV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:32784326 |texte= Effective Use of Angiotensin II in Coronavirus Disease 19-Associated Mixed Shock State: A Case Report. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32784326" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a CovidSeniorV1
![]() | This area was generated with Dilib version V0.6.37. | ![]() |